Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Coding Corner Question

From the College  |  Issue: August 2008  |  August 1, 2008

A physician assistant (PA) sees a 72-year-old female patient for a routine follow-up visit. The patient was previously seen by the rheumatologist, who diagnosed her with osteoarthritis and initiated treatment.

The patient is currently on celecoxib and ranitidine and reports that her right knee has been more swollen and stiff in the past three weeks. She had an intraarticular injection of her knee six months ago, with marked improvement in pain and swelling. The patient also mentions that she has abdominal pain and nausea after she takes the celecoxib and has never experienced this before.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

On examination, the patient is alert and oriented. Vital signs are normal. Height is 5’7”, weight is 140 pounds, and body mass index is 21.9. Head, eye, ear, nose, and throat exam is normal. There is no lymphadenopathy and her lungs are clear. Her heart is regular rate and rhythm, no murmurs or friction rubs. She has good peripheral pulses and her abdomen is soft, non-tender, and had no mass or hepatosplenomegaly.

The patient’s physical examination is remarkable for a large effusion of the right knee. The physician is not available to examine the patient at this time, so the PA explains therapeutic options to the patient, including risks and benefits of continuing treatment with celecoxib, and performs an aspiration of the right knee with Synvisc injection. The patient is taken off celecoxib.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The PA writes a new prescription for the pain and gives the patient discharge instructions on post-arthrocentesis care and follow up. The rheumatologist is in the office suite at the time the PA sees the patient, but has no direct involvement in the patient’s evaluation and management during this visit.

Considering that the patient has Medicare insurance, how would you code this?

Click here for the answer.

Share: 

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:BillingCodingOsteoarthritisPain

Related Articles

    Rheumatology Drug Updates: Celecoxib and Cardiovascular Safety Trial Results Reviewed

    December 13, 2016

    Nonsteroidal anti-inflammatory drugs (NSAIDs) have been used therapeutically since the 1960s.1 Evidence of adverse cardiovascular outcomes led to the withdrawal of the selective COX-2 inhibitor rofecoxib in September 2004, when the question of cardiovascular safety of NSAIDs first came into the limelight.2 Valdecoxib (Bextra) was subsequently withdrawn from the market in April 2005 due to…

    Celecoxib & Cardiovascular Death: NSAID Safety Under Review

    December 7, 2016

    A recent study showed that at moderate doses celecoxib may be noninferior with respect to cardiovascular safety compared with ibuprofen or naproxen…

    Celecoxib Is a Safe Treatment for Arthritis

    February 20, 2017

    A study compared celecoxib with ibuprofen and naproxen to determine its cardiovascular safety, as well as gastrointestinal and renal outcomes, in patients with rheumatoid arthritis and osteoarthritis. The results showed that celecoxib met all prespecified noninferiority requirements and is as safe as other non-selective NSAIDs…

    A Comprehensive Review of NSAID Cardiovascular Toxicity

    A Comprehensive Review of NSAID Cardiovascular Toxicity

    July 18, 2018

    Non-steroidal anti-inflammatory drugs (NSAIDs) are the most used drugs for acute and chronic pain. More than 30 billion doses of NSAIDs are consumed annually from more than 70 million prescriptions.1 Despite their common use, NSAIDs are not free of serious toxicities. In the pre-Vioxx (rofecoxib) era, gastrointestinal toxicity was the primary concern for many NSAIDs….

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences